Vision loss is one of the earliest, and it is the most consistent feature, of Bardet-Biedl Syndrome (BBS), typically beginning in childhood with night blindness and progressive cone-rod dystrophy. This retinal degeneration affects both central and peripheral vision over time and often leads to legal blindness in adolescence or early adulthood.
The underlying cause is dysfunction of the photoreceptor cilia, which are critical for normal retinal signaling. The exact molecular pathways leading to photoreceptor degeneration are not fully elucidated, research strongly suggests that defective protein and lipid trafficking within the photoreceptor cilium plays a central role. On fundus examination, features may include attenuated retinal vessels, pale optic discs, and pigmentary changes resembling retinitis pigmentosa, though with a broader spectrum in BBS.
The degree and progression of vision loss in Bardet-Biedl Syndrome (BBS) can vary widely, not only between individuals but also depending on the specific genetic subtype involved. For example, individuals with BBS1 may experience a slower decline in visual function compared to those with BBS10 or other subtypes, where retinal degeneration can be more rapid and severe. These differences likely reflect underlying variations in how each BBS gene affects ciliary structure and photoreceptor maintenance, emphasizing the importance of genetic diagnosis in anticipating visual outcomes and guiding supportive care.
Therapeutic avenues
No cure has currently been approved by any regulatory body. Low-vision aids, mobility training, and regular ophthalmologic follow-up can significantly improve quality of life. Gene therapy research is ongoing, particularly targeting common BBS subtypes like BBS1 and BBS10.
The vision loss of BBS is broadly comparable to a group of inherited causes of blindness called retinitis pigmentosa, or RP. Given that RP is now a leading cause of blindness, the pharmaceutical industry has been interested in developing therapies that address the entire RP group of genetic diseases. As of 2025, a wide range of therapies are in the pipeline, some in more advanced stages, that are targeting retinitis pigmentosa in a gene agnostic manner, and may thus be useful to BBS patients. For more information on RP and the therapies in the pipeline, please see https://rp-hub.org/
In addition to therapies targeting RP, there are therapies specifically targeting the retinal degradation of BBS. Although preclinical research on BBS1 and BBS10 mouse models has confirmed the highly promising benefits of gene therapy, these studies are still in preclinical phases as of early 2025.
Last, but not least, BBS patients may and should look to lifestyle changes and commercially available compounds (supplements) in an attempt to slow the currently inevitable progression of the disease, some of which are backed by strong evidence in mouse models or even human trials.
Vision loss — simple summary
- Vision loss is widespread in BBS. There are no documented cases in the medical literature of individuals with BBS who retain completely normal vision.
- The degree of vision loss varies significantly across BBS genetic subtypes (BBS1, BBS10, etc.) but also significantly within BBS subtypes. Therefore, the pace of the progression of the disease (i.e. the speed of vision loss) cannot reliably be predicted.
- No approved cure exists for BBS-related vision loss (per 2025).
- Lifestyle changes and supplements may help slow disease progression; some show promising results in animal studies and early trials. On this website we list NAC, DHA, and TUDCA. We consider these the most relevant ones for BBS, but a long list of other supplements targeting RP generally can be found at: https://rp-hub.org/
- Therapies being developed for retinitis pigmentosa (RP) may benefit BBS patients, as the retinal degeneration in BBS resembles RP. The RP pipeline is found at https://rp-hub.org/
- BBS-specific gene therapy—especially for BBS1 and BBS10—is under active preclinical investigation, but may take another 5-10 years to be commercially available.